Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation - 05/02/20
, DaJuanicia N. Holmes, MS b, Peter Shrader, MS b, Laine Thomas, PhD b, Gregg C. Fonarow, MD c, Kenneth W. Mahaffey, MD d, Bernard J Gersh, MB, Ch.B., D.Phil. e, Peter R. Kowey, MD f, Gerald V. Naccarelli, MD g, James V. Freeman, MD h, Daniel E. Singer, MD i, Jeffrey B. Washam, PhD a, Eric D. Peterson, MD, MPH a, b, Jonathan P. Piccini, MD, MHS a, b, James A. Reiffel, MD jAbstract |
Background |
Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects.
Methods |
Using the ORBIT AF registry, patients with AF on amiodarone at enrollment, prescribed amiodarone during follow-up, or never on amiodarone were analyzed for the proportion treated with a guideline-based indication for amiodarone, the variability in amiodarone use across sites, and the outcomes (mortality, hospitalization, and stroke) among patients treated with amiodarone. Hierarchical logistic regression modeling with site-specific random intercepts compared rates of amiodarone use across 170 sites. A logistic regression model for propensity to receive amiodarone created a propensity-matched cohort. Cox proportional hazards modeling, stratified by matched pairs evaluated the association between amiodarone and outcomes.
Results |
Among 6,987 AF patients, 867 (12%) were on amiodarone at baseline and 451 (6%) started on incident amiodarone during the 3-year follow-up. Use of amiodarone varied among sites from 3% in the lowest tertile to 21% in the highest (p<0.0001). Among those treated, 32% had documented contraindications to other AADs or had failed another AAD in the past. Mortality, cardiovascular hospitalization, and stroke were similar among matched patients on and not on amiodarone at baseline, while incident amiodarone use in matched patients was associated with higher all-cause mortality (adjusted HR 2.06, 95% CI 1.35-3.16).
Conclusions |
Use of amiodarone among AF patients in community practice is highly variable. More than 2 out of 3 patients treated with amiodarone appeared to be eligible for a different AAD.
Le texte complet de cet article est disponible en PDF.Plan
| Guest Editor: Stuart J. Connolly, MD, served as guest editor for this article. |
Vol 220
P. 145-154 - février 2020 Retour au numéro
Article précédent
- High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction
- Jay S. Shavadia, Christopher B. Granger, Wendimagegn Alemayehu, Cynthia M. Westerhout, Thomas J. Povsic, Sorin J. Brener, Sean van Diepen, Christopher Defilippi, Paul W. Armstrong
- Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction
- Dan Yang, Connor Galen O'Brien, Gentaro Ikeda, Jay H. Traverse, Doris A. Taylor, Timothy D. Henry, Roberto Bolli, Phillip C. Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?